These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 9849484)

  • 21. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Sandler E; Lyden E; Ruymann F; Maurer H; Wharam M; Parham D; Link M; Crist W
    Med Pediatr Oncol; 2001 Nov; 37(5):442-8. PubMed ID: 11745872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
    Felgenhauer J; Hawkins D; Pendergrass T; Lindsley K; Conrad EU; Miser JS
    Med Pediatr Oncol; 2000 Jan; 34(1):29-38. PubMed ID: 10611582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
    J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
    J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Womer RB; West DC; Krailo MD; Dickman PS; Pawel BR; Grier HE; Marcus K; Sailer S; Healey JH; Dormans JP; Weiss AR
    J Clin Oncol; 2012 Nov; 30(33):4148-54. PubMed ID: 23091096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    ; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
    J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vincristine, doxorubicin, cyclophosfamide, actinomycin D, ifosfamide, and etoposide in adult and pediatric patients with nonmetastatic Ewing sarcoma. Final results of a monoinstitutional study.
    Ferrari S; Palmerini E; Alberghini M; Staals E; Mercuri M; Barbieri E; Longhi A; Cantero L; Cesari M; Abate M; Balladelli A; Picci P; Bacci G
    Tumori; 2010; 96(2):213-8. PubMed ID: 20572576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
    Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
    J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
    Smith SC; Lindsley SK; Felgenhauer J; Hawkins DS; Douglas JG
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):774-9. PubMed ID: 14528099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.
    Bisogno G; Jenney M; Bergeron C; Gallego Melcón S; Ferrari A; Oberlin O; Carli M; Stevens M; Kelsey A; De Paoli A; Gaze MN; Martelli H; Devalck C; Merks JH; Ben-Arush M; Glosli H; Chisholm J; Orbach D; Minard-Colin V; De Salvo GL;
    Lancet Oncol; 2018 Aug; 19(8):1061-1071. PubMed ID: 29941280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Brennan B; Kirton L; Marec-Bérard P; Gaspar N; Laurence V; Martín-Broto J; Sastre A; Gelderblom H; Owens C; Fenwick N; Strauss S; Moroz V; Whelan J; Wheatley K
    Lancet; 2022 Oct; 400(10362):1513-1521. PubMed ID: 36522207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study.
    Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC
    J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Cost-effectiveness of Outpatient Administration of High-dose Chemotherapy in Children With Ewing Sarcoma.
    Elshahoubi A; Alnassan A; Sultan I
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):e152-e154. PubMed ID: 30608490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
    Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 39. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
    Klingebiel T; Boos J; Beske F; Hallmen E; Int-Veen C; Dantonello T; Treuner J; Gadner H; Marky I; Kazanowska B; Koscielniak E
    Pediatr Blood Cancer; 2008 Apr; 50(4):739-45. PubMed ID: 18286501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.